Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Malignant Lymphomas”

443 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 443 results

Early research (Phase 1)WithdrawnNCT04500548
What this trial is testing

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch Syndrome+9 more
National Cancer Institute (NCI)
Early research (Phase 1)Not Yet RecruitingNCT07478848
What this trial is testing

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Who this might be right for
Large B Cell LymphomaNon Hodgkin Lymphoma (NHL)Diffuse Large B Cell Lymphoma (DLBCL)+2 more
Abramson Cancer Center at Penn Medicine 14
Testing effectiveness (Phase 2)Study completedNCT00448201
What this trial is testing

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 71
Testing effectiveness (Phase 2)WithdrawnNCT01415765
What this trial is testing

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Who this might be right for
Lymphoma, Diffuse Large-Cell B-cellDiffuse, Large B-cell LymphomaLymphoma, Diffuse Large-Cell+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Early research (Phase 1)Study completedNCT00003962
What this trial is testing

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Study completedNCT00042666
What this trial is testing

Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Who this might be right for
Non-Hodgkin's Lymphoma
Eli Lilly and Company 55
Testing effectiveness (Phase 2)Study completedNCT03213678
What this trial is testing

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+30 more
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT02030834
What this trial is testing

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Who this might be right for
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
University of Pennsylvania 63
Testing effectiveness (Phase 2)Study completedNCT02249429
What this trial is testing

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Who this might be right for
Lymphoma, Malignant
PIQUR Therapeutics AG 53
Testing effectiveness (Phase 2)Looking for participantsNCT04067336
What this trial is testing

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Advanced Malignant NeoplasmAcute Myeloid LeukemiaMixed Lineage Leukemia+4 more
Kura Oncology, Inc. 263
Very early researchStudy completedNCT02846935
What this trial is testing

P53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Who this might be right for
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's Lymphomas+1 more
Yogen Saunthararajah 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT03233204
What this trial is testing

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+33 more
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Ended earlyNCT00005852
What this trial is testing

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
H. Lee Moffitt Cancer Center and Research Institute
Early research (Phase 1)Looking for participantsNCT03113643
What this trial is testing

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 72
Testing effectiveness (Phase 2)Study completedNCT00109993
What this trial is testing

Campath-1H + FK506 and Methylprednisolone for GVHD

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
Case Comprehensive Cancer Center 34
Early research (Phase 1)Ended earlyNCT03379493
What this trial is testing

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Who this might be right for
Lymphomas Non-Hodgkin's B-Cell
Eureka Therapeutics Inc. 4
Testing effectiveness (Phase 2)Looking for participantsNCT07022964
What this trial is testing

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

Who this might be right for
T-Cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07326371
What this trial is testing

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Ruijin Hospital 24
Load More Results